Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk 4 months ago
NewsInitiationAnalyst RatingsPrice Target
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.